Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Treatment Intensification in Type 2 Diabetes: A Real-World Study of 2-OAD Regimens, GLP-1 RAs, or Basal Insulin

Treatment Intensification in Type 2 Diabetes: A Real-World Study of 2-OAD Regimens, GLP-1 RAs, or... Diabetes Ther (2018) 9:1169–1184 https://doi.org/10.1007/s13300-018-0429-x ORIGINAL RESEARCH Treatment Intensification in Type 2 Diabetes: A Real- World Study of 2-OAD Regimens, GLP-1 RAs, or Basal Insulin . . . . Lawrence Blonde Denis Raccah Elisheva Lew Juliana Meyers . . . . Elena Nikonova Mayank Ajmera Keith L. Davis Monica Bertolini Bruno Guerci Received: January 23, 2018 / Published online: April 19, 2018 The Author(s) 2018 receptor agonists (GLP-1 RAs), or basal insulin ABSTRACT in a real-world setting. Methods: Adults with T2D on OAD monother- Introduction: Treatment guidelines recom- apy were identified in the MarketScan claims mend a stepwise approach to glycemia man- database (2007–2014). Those initiating two agement in patients with type 2 diabetes (T2D), OADs (simultaneously or sequentially), GLP-1 but this may result in uncontrolled glycated RAs, or basal insulin were selected (date of ini- hemoglobin A1c (HbA1c) between steps. This tiation was termed the ‘index date’); patients retrospective analysis compared clinical and were required to have HbA1c [ 7.0% in the economic outcomes among patients with 6 months pre-index date. HbA1c was compared uncontrolled T2D initiating two oral antidia- from 6 months pre- to 1-year post-index. betes drugs (OADs), glucagon-like peptide-1 Annual all-cause healthcare utilization and costs http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Diabetes Therapy Springer Journals

Treatment Intensification in Type 2 Diabetes: A Real-World Study of 2-OAD Regimens, GLP-1 RAs, or Basal Insulin

Free on Publisher Site
16 pages

Loading next page...
 
/lp/springer_journal/treatment-intensification-in-type-2-diabetes-a-real-world-study-of-2-usmhhnPeq0
Publisher
Springer Journals
Copyright
Copyright © 2018 by The Author(s)
Subject
Medicine & Public Health; Internal Medicine; Diabetes; Cardiology; Endocrinology
ISSN
1869-6953
eISSN
1869-6961
DOI
10.1007/s13300-018-0429-x
Publisher site
See Article on Publisher Site

Abstract

Diabetes Ther (2018) 9:1169–1184 https://doi.org/10.1007/s13300-018-0429-x ORIGINAL RESEARCH Treatment Intensification in Type 2 Diabetes: A Real- World Study of 2-OAD Regimens, GLP-1 RAs, or Basal Insulin . . . . Lawrence Blonde Denis Raccah Elisheva Lew Juliana Meyers . . . . Elena Nikonova Mayank Ajmera Keith L. Davis Monica Bertolini Bruno Guerci Received: January 23, 2018 / Published online: April 19, 2018 The Author(s) 2018 receptor agonists (GLP-1 RAs), or basal insulin ABSTRACT in a real-world setting. Methods: Adults with T2D on OAD monother- Introduction: Treatment guidelines recom- apy were identified in the MarketScan claims mend a stepwise approach to glycemia man- database (2007–2014). Those initiating two agement in patients with type 2 diabetes (T2D), OADs (simultaneously or sequentially), GLP-1 but this may result in uncontrolled glycated RAs, or basal insulin were selected (date of ini- hemoglobin A1c (HbA1c) between steps. This tiation was termed the ‘index date’); patients retrospective analysis compared clinical and were required to have HbA1c [ 7.0% in the economic outcomes among patients with 6 months pre-index date. HbA1c was compared uncontrolled T2D initiating two oral antidia- from 6 months pre- to 1-year post-index. betes drugs (OADs), glucagon-like peptide-1 Annual all-cause healthcare utilization and costs

Journal

Diabetes TherapySpringer Journals

Published: Apr 19, 2018

References